iPSC-based research in ALS precision medicine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37267911.
- Also identified by DOI 10.1016/j.stem.2023.05.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Induced Pluripotent Stem Cells